AtriCure (ATRC) Projected to Post Quarterly Earnings on Thursday

AtriCure (NASDAQ:ATRC - Get Free Report) is expected to release its earnings data after the market closes on Thursday, February 20th. Analysts expect AtriCure to post earnings of ($0.23) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

AtriCure Trading Up 3.4 %

Shares of NASDAQ ATRC traded up $1.35 during mid-day trading on Friday, reaching $40.94. The company had a trading volume of 577,628 shares, compared to its average volume of 590,066. AtriCure has a 52 week low of $18.94 and a 52 week high of $43.11. The business's 50-day moving average is $35.76 and its 200-day moving average is $31.50. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -49.33 and a beta of 1.46. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Piper Sandler upped their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday. Stifel Nicolaus upped their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on shares of AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Canaccord Genuity Group upped their price objective on shares of AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.56.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.